Business

Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process

Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process

articleShanghai Allist Pharmaceuticals Co. Ltd. Class AJuly 9, 20255/news/announcement-on-voluntary-disclosure-of-proposed-inclusion-of-furmonertinib-mesylate-tablets-for-second-line-treatment-of-egfr-exon-20-insertion-mutation-nsclc-in-the-priority-review-process
Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process

About this update from Shanghai Allist Pharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review ProcessThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shanghai Allist Pharmaceuticals Co. Ltd. Class A